Company / PP&E per Share
CRISPR Therapeutics AG PP&E per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$1.21
FY2025
5-year range
$1.21 / $2.08
FY2021-FY2025
Trend
-22.8%
vs FY2024
Sector context
#44 of 193
Health Care
What the data says
CRISPR Therapeutics AG's pp&e per share of $1.21 is higher than 77% of companies in the Health Care sector (FY2025). PP&E per Share has declined for 3 consecutive years, from $2.08 in FY2022 to $1.21 in FY2025.
Based on SEC 10-K filings.
1.21 in FY2025 with a 5-year CAGR of +16.2%. Top quartile in the Health Care sector.
Declined from $1.90 to $1.21 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- +16.2%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 193This company $1.21 Sector average $22.13
▼
-94.5% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's pp&e per share has declined for 3 consecutive years.
- In FY2025, pp&e per share decreased 22.8% year-over-year.
- Ranks #44 out of 193 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.21 | -22.8% |
| FY2024 | $1.56 | -17.6% |
| FY2023 | $1.90 | -8.9% |
| FY2022 | $2.08 | +16.6% |
| FY2021 | $1.79 | +213.3% |
| FY2020 | $0.57 | -5.6% |
| FY2019 | $0.60 | +32.6% |
| FY2018 | $0.46 | -4.0% |
| FY2017 | $0.47 | -87.5% |
| FY2016 | $3.80 | +1342.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026